NeuroThera Labs Inc.

NTLX · V · Healthcare / Drug Manufacturers - General

3.55CAD+0.18 (+5.34%)

Price History

Full chart

Market Stats

Previous Close3.37

Open3.48

Day Range3.48 – 4.00

52-Week Range2.10 – 5.32

Volume14.70K

Market Cap373.56M

P/E (TTM)0.00

Forward P/E0.00

EPS-1.21

Dividend Yield0.00%

Beta-0.11

50-Day Avg4.13

200-Day Avg2.97

About

Neurothera Labs Inc. engages in the development of a portfolio of drugs based on cannabinoid molecules. The company develops programs based on tetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder, and status epilepticus. It also focuses on e-commerce operations, which sells hemp-based products. Neurothera Labs Inc. was formerly known as Miza III Ventures Inc. The company is based in Newark, Delaware. Neurothera Labs Inc. is a subsidiary of SciSparc Ltd.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - General
CEOMr. Oz Adler C.P.A.
Headquarters18 Shea Way, Newark, DE, United States, 19713, Canada
Websitehttps://www.neurothera.com

Leadership

Mr. Gabriel KabazoCFO & Corporate Secretary · b. 1973
Mr. Oz Adler C.P.A.Chief Executive Officer · b. 1987
Michal EfratyIR Manager

Financials

Income Statement

Currency: USD	2022-01-31	2023-01-31	2024-01-31	2025-01-31	2026-01-31
Total Revenue	0	0	0	0	856.00K
Cost of Revenue	-	-	-	800.00K	225.00K
Gross Profit	-	-	-	506.00K	631.00K
Gross Margin	-	-	-	-	73.71%
Operating Expense	-	-	-	682.20K	4.78M
Operating Income	-149.87K	-79.78K	-78.05K	-176.20K	-4.15M
Operating Margin	-	-	-	-	-484.46%
EBITDA	-	-	-78.05K	-176.20K	-4.03M
EBITDA Margin	-	-	-	-	-470.21%
Net Income	-152.79K	-79.86K	-78.13K	-176.24K	-4.12M
Net Income Margin	-	-	-	-	-481.66%
R&D	-	-	-	1.71M	1.80M
R&D as % of Total Revenue	-	-	-	-	210.40%
Interest Expense	-	-	-	0	125.00K
Interest Expense % of Total Revenue	-	-	-	-	14.60%

Balance Sheet

Currency: USD	2022-01-31	2023-01-31	2024-01-31	2025-01-31	2026-01-31
Total Assets	1.37M	1.28M	911.31K	745.52K	3.03M
Total Liabilities	17.65K	9.15K	30.82K	107.62K	2.38M
Total Equity	1.35M	1.27M	880.49K	637.90K	134.00K
Cash	1.36M	1.28M	910.35K	744.64K	1.70M

Cash Flow

Currency: USD	2022-01-31	2023-01-31	2024-01-31	2025-01-31	2026-01-31
Operating Cash Flow	-109.79K	-80.86K	-52.58K	-97.12K	-1.66M
Financing Cash Flow	1.33M	0	7.46K	0	2.53M
Capital Expenditure	0	0	0	0	0
Free Cash Flow	-109.79K	-80.86K	-52.58K	-97.12K	-1.66M
FCF to OCF	100.00%	100.00%	100.00%	100.00%	100.00%

Earnings

Report Date	Jan 28, 2027
EPS Estimate	-
EPS Actual	-
Surprise	-
Timing	After-hours

Key Statistics & Ratios

Market Cap373.56M

Enterprise Value60.40M

Trailing P/E0.00

Forward P/E0.00

Price / Sales549.35

Price / Book13.79

EPS-1.21

Book Value0.4183

Revenue (TTM)680.00K

Gross Profit (TTM)484.00K

EBITDA-3.66M

Profit Margin0.00%

Operating Margin-783.86%

Return on Equity-399.18%

Return on Assets-71.32%

Shares Outstanding84.90M

Shares Float7.54M

Beta-0.11

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Sep 2, 20261:14